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ABSTRACT Mycoplasma species are responsible for several economically significant
livestock diseases for which there is a need for new and improved vaccines. Most of
the existing mycoplasma vaccines are attenuated strains that have been empirically
obtained by serial passages or by chemical mutagenesis. The recent development of
synthetic biology approaches has opened the way for the engineering of live myco-
plasma vaccines. Using these tools, the essential GTPase-encoding gene obg was
modified directly on the Mycoplasma mycoides subsp. capri genome cloned in yeast,
reproducing mutations suspected to induce a temperature-sensitive (TS) pheno-
type. After transplantation of modified genomes into a recipient cell, the phenotype
of the resulting M. mycoides subsp. capri mutants was characterized. Single-point
obg mutations did not result in a strong TS phenotype in M. mycoides subsp. capri,
but a clone presenting three obg mutations was shown to grow with difficulty at
temperatures of 40°C. This particular mutant was then tested in a caprine septice-
mia model of M. mycoides subsp. capri infection. Five out of eight goats infected
with the parental strain had to be euthanized, in contrast to one out of eight goats
infected with the obg mutant, demonstrating an attenuation of virulence in the mu-
tant. Moreover, the strain isolated from the euthanized animal in the group infected
with the obg mutant was shown to carry a reversion in the obg gene associated
with the loss of the TS phenotype. This study demonstrates the feasibility of build-
ing attenuated strains of mycoplasma that could contribute to the design of novel
vaccines with improved safety.
IMPORTANCE Animal diseases due to mycoplasmas are a major cause of morbidity
and mortality associated with economic losses for farmers all over the world. Cur-
rently used mycoplasma vaccines exhibit several drawbacks, including low efficacy,
short time of protection, adverse reactions, and difficulty in differentiating infected
from vaccinated animals. Therefore, there is a need for improved vaccines to control
animal mycoplasmoses. Here, we used genome engineering tools derived from syn-
thetic biology approaches to produce targeted mutations in the essential GTPase-
encoding obg gene of Mycoplasma mycoides subsp. capri. Some of the resulting mu-
tants exhibited a marked temperature-sensitive phenotype. The virulence of one of
the obg mutants was evaluated in a caprine septicemia model and found to be
strongly reduced. Although the obg mutant reverted to a virulent phenotype in one
infected animal, we believe that these results contribute to a strategy that should
help in building new vaccines against animal mycoplasmoses.
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Mycoplasma diseases continue to be a major problem in the livestock sectorworldwide. Among the most serious diseases, one can cite contagious bovine and
caprine pleuropneumonia, contagious agalactia in small ruminants, enzootic pneumo-
nia in pigs, and chronic respiratory disease in poultry. The socioeconomic cost of these
infectious diseases is due mostly to mortality, decreased productivity, trade restrictions,
and the costs associated with disease control. The measures currently being pursued
for curbing mycoplasma disease mainly rely on antibiotic treatments and prophylaxis,
including vaccines if available. Vaccines constitute the most cost-effective measure to
control livestock mycoplasma diseases, especially considering increasing antimicrobial
resistance, as reported for Mycoplasma (1) and other bacteria.
Mycoplasma vaccines have been used for decades, but little progress has been
made in developing vaccines that are more efficient and induce long-lasting immunity.
Most commercially available mycoplasma vaccines are still made of attenuated myco-
plasma strains, obtained after serial passaging of the pathogen, and are generally
characterized by their lack of efficacy and the production of adverse reactions (for a
review, see reference 2). This is particularly true for ruminant diseases caused by
Mycoplasma species belonging to the Mycoplasma mycoides cluster (3). Recently,
temperature-sensitive (TS) mutants have been widely used for the control of myco-
plasmoses in poultry. Most of these vaccines were initially obtained by empirical
chemical mutagenesis. This is the case for the attenuated strain of Mycoplasma syno-
viae, MS-H, that has been used as a commercial poultry vaccine (Vaxsafe MS; Bioprop-
erties Pty. Ltd., Ringwood, Victoria, Australia) in several countries (4). The TS pheno-
type has been proposed as a general strategy to design live vaccines (for a review, see
reference 5). Interestingly, a genome comparison between M. synoviae strains has
indicated that the temperature sensitivity of MS-H is associated with a single-nucleotide
change resulting in a Gly123Arg substitution in the Obg sequence (6). The obg gene
encodes an essential P-loop GTPase in all bacteria. The Obg protein (Spo0B-associated
GTP-binding protein) acts as a sensor of the GDP/GTP pools and participates in central
processes that affect essential cellular functions (7, 8). Recent studies also suggest a role
connecting ribosome assembly with the stress response, since it was shown in Esche-
richia coli that Obg interacts with both the 50S ribosomal subunit and the stringent
response alarmone (p)ppGpp (guanosine penta/tetraphosphate) (9).
The direct implication of obg mutations in the TS phenotype in Mycoplasma
species, including in M. synoviae, has not yet been completely demonstrated (10), as
there is a lack of genetic tools for producing mutants. However, other studies con-
ducted using model organisms such as Escherichia coli (8) and Bacillus subtilis (11)
revealed that mutations of the Obg protein have been associated with a TS pheno-
type. The Obg protein structure has been determined for B. subtilis (12) and for Thermus
thermophilus (13). Interestingly, almost all mutations identified so far, associated with a
TS phenotype, have been located in the N-terminal part of the Obg protein (8, 14).
These results, combined with the universality of Obg in bacteria, reinforce the
emergence of new therapeutic strategies targeting this essential bacterial GTPase (15).
In this study, we used synthetic biology approaches to generate a series of targeted
mutations in the obg gene of Mycoplasma mycoides subsp. capri strain GM12. These
changes comprised the mutations known to induce a TS phenotype in both E. coli and
B. subtilis as well as the mutation suspected of being involved in the TS phenotype of
the M. synoviae vaccine strain. The temperature sensitivity of the resulting M. mycoides
subsp. capri mutants was characterized in vitro. A mutant that showed the strongest
TS phenotype was selected and finally tested to evaluate its effect on virulence and
pathogenicity using a caprine challenge model. Our results strongly suggest that this
mutant is attenuated and demonstrate the feasibility of using synthetic biology ap-
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proaches to design attenuated next-generation vaccines that express their normal
repertoire of antigens and are safe.
RESULTS
Selection of the targeted mutations in the M. mycoides subsp. capri obg gene.
The protein encoded by the obg gene is essential for cell viability in all bacterial species
tested so far (16). For mycoplasma species, this essentiality was confirmed in M.
pulmonis (17),M. genitalium (18), andM. pneumoniae (19). In the synthetic version of the
M. mycoides subsp. capri genome constructed at the J. Craig Venter Institute (JCVI-
syn1.0), the obg gene was shown to be essential in global transposon mutagenesis
assays and was retained in the half-reduced genome of the derivative JCVI-syn3.0 (20).
The obg gene in the genome of M. mycoides subsp. capri strain GM12 encodes a
433-amino-acid (aa) protein structured into three domains (see Fig. S1A in the supple-
mental material). An alignment of the entire M. mycoides subsp. capri Obg amino acid
sequence with other bacterial Obg protein sequences shows only moderate conserva-
tion, with identity percentages ranging from 44.9% with M. synoviae Obg to 41.8% with
E. coli and B. subtilis Obg and 37.7% with T. thermophilus Obg (Fig. S1B). However, the
identity scores increase up to50% with M. synoviae and B. subtilis Obg proteins when
considering the Obg fold and GTP-binding domains only (Fig. S1B). In M. synoviae, the
mutation that has been associated with a TS phenotype is a Gly123Arg substitution
(6). We chose to produce the same mutation in the M. mycoides subsp. capri obg gene
using two different changes in the nucleotide sequence: either GGGAGA or
GGGCGT. In addition, we produced the mutations Gly80Glu (GGTGAG) and
Asp85Asn (GATAAC) that have been reported to be associated with a TS phenotype
in B. subtilis (Gly80Glu and Asp85Asn) (11), E. coli (Gly80Glu and Asp85Asn) (8), and
Caulobacter crescentus (Gly80Glu only) (21) (Fig. 1A). We included two nucleotide
changes per codon to limit the possibility of reversion during both the in vitro and in
vivo cell propagation. It should be noted that even though the targeted Gly123, Gly80,
and Asp85 residues are conserved between M. mycoides subsp. capri, M. synoviae, B.
subtilis, and E. coli, the amino acid numbering slightly differs from one organism to
another. Throughout this text, the numbering of the positions of the residues in the M.
mycoides subsp. capri Obg sequence was adopted to avoid confusion.
Generation of M. mycoides subsp. capri obg mutants. Figure 1B shows the
general experimental strategy conducted in this study that led to the generation of the
different TS M. mycoides subsp. capri mutants as well as the different validation
methods used at each step. Each of the above-mentioned substitutions was introduced
into the parental M. mycoides subsp. capri genome (strain GM12) formerly cloned into
yeast (YCpMmyc1.1) (22), using the TREC-IN (tandem repeat endonuclease cleavage-
insertion) method, an approach allowing seamless gene replacement in yeast (Fig. 1B,
step 1, and Fig. S2). Yeast transformants were screened by PCR, and the amplicons
covering the obg region were sequenced to confirm the presence of the designed
mutations (Fig. S3). One of the yeast transformants (clone 43 [cl43]), isolated initially to
obtain the GGGAGA (Gly124Arg) mutant, carried additional point mutations. Indeed,
this particular clone presented four mutations in total, three in the obg gene, GATGGT
(Asp85Gly), GGGAGA (Gly124Arg), and TATTGT (Ile244Val), and one in the down-
stream nadE gene that encodes a putative NH3-dependent NAD synthetase
(CAACGA [Gln7Arg]). Because of the presence of mutations at two targeted positions
(Gly124Arg and Asp85Gly), yeast clone 43 was subjected to further analysis. In order to
take into account any potential impact of the substitution located on the nadE gene, an
additional yeast clone (cl19) was constructed by repairing this substitution (Fig. S4).
Genome integrity was verified by multiplex PCR and pulsed-field gel electrophoresis
(PFGE) (Fig. S3 and S4), and six yeast clones (cl2, cl37, cl80, cl69, cl43, and cl19) carrying
each the modified M. mycoides subsp. capri genomes were selected.
The modified M. mycoides subsp. capri genomes were isolated from the yeast clones
and independently transplanted into McapΔRE recipient cells (Fig. 1B, step 2). The
resulting transplants were serially cultured for three passages, and their genomes were
obg Mutations Result in Attenuation of Mycoplasma
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FIG 1 Global strategy used to produce M. mycoides subsp. capri obg mutants. (A) Residues targeted in the M. mycoides subsp. capri Obg protein during this
study. The amino acid changes targeted in this study (Gly80Glu, Asp85Asn, and Gly124Arg) were all located in the N-terminal end of the Obg protein. The
Gly80Glu (mutant 7.1) and Asp85Asn (mutant 11.1) substitutions were produced using the nucleotide changes GGTGAG and GATAAC, respectively. The
Gly124Arg substitution was produced using two different changes in the nucleotide sequence, either GGGAGA (mutant 15.2) or GGGCGT (mutant 69.3).
Unexpectedly, one clone (43.7) from the plate for obtaining the Gly124Arg (GGGAGA) substitution showed three other mutations, two in the obg gene,
Ile244Val (TATTGT) and Asp85Gly (GATGGT), and one in the neighboring nadE gene, Gln7Arg (CAACGA). The latter mutation was repaired and resulted
(Continued on next page)
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sequenced to confirm the expected substitutions on the obg gene. Altogether, six M.
mycoides subsp. capri obgmutants were finally selected for phenotypic characterization
(Fig. 1B, step 3), with four presenting a single-amino-acid substitution (mutants 7.1,
11.1, 15.2, and 69.3) and two presenting multiple substitutions (mutants 43.7 and 9.2)
(Fig. 1A and Table 1).
Phenotypic characterization of the M. mycoides subsp. capri obg mutants. The
impact of the above-mentioned obg substitutions on M. mycoides subsp. capri growth
was evaluated by combining culture assays and quantitative PCR (qPCR) analyses. AllM.
mycoides subsp. capri obg mutants were cultivated in standard SP5 mycoplasma
medium at 32°C and 40°C together with the parental clone 30.1 (YCpMmyc1.1 with a
wild-type [WT] obg region) as a control. The color change of the medium was first
observed daily during 8 consecutive days (48-h and 144-h time points are shown in
Fig. 2). Similarly to WT M. mycoides subsp. capri strain GM12 (data not shown), the
control clone 30.1 grew slightly faster at 40°C than at 32°C and reached a maximum
titer (109 color-changing units [CCU] · ml1) after 48 h of incubation at 40°C. Unex-
pectedly, the M. mycoides subsp. capri obg mutants 11.1, 15.2, and 69.3 with the
FIG 1 Legend (Continued)
in mutant 9.2. (B) Scheme of the general experimental strategy followed in this study. The YCpMmyc1.1 genome was previously cloned into the yeast strain
VL6-48N (7). The replacement of the essential obg gene in the YCpMmyc1.1 genome was achieved using TREC-IN, a three-step method allowing the seamless
knock-in of the target gene(s) on bacterial genomes cloned into yeast (10). After modification, M. mycoides subsp. capri (Mmc) obg-mutated genomes
(YCpMmyc1.1-obgmod) were isolated from yeast and transplanted into restriction-free M. capricolum subsp. capricolum recipient cells (McapΔRE) to obtain M.
mycoides subsp. capri obgmutants characterized by mutation at a precise position within the obg gene. Mutants and filter-cloned derivatives were characterized
in vitro (genotypic and phenotypic analyses). The M. mycoides subsp. capri obg subclone that showed the most temperature-sensitive phenotype (t) was
selected for animal experiments using goats.
TABLE 1M. mycoides subsp. capri obg mutants and subclones obtained in this studyc
M. mycoides
subsp. capri
obg mutant
obg
nucleotide
change(s)
(position)a
Obg
amino acid
change(s)a
NadE
amino acid
change
TS
phenotype
of mutantb
M. mycoides
subsp. capri
obg subclone
TS
phenotype
of cloneb
11.1 GATAAC
(253/255)
Asp85Asn None ND ND
15.2 GGGCGT
(369/371)
Gly124Arg None ND ND
69.3 GGGAGA
(369/371)
Gly124Arg None ND ND
7.1 GGTGAG
(239/240)
Gly80Glu  7.1.2A 
7.1.3A 
43.7 GATGGT
(254),
GGGAGA
(369/371),
ATAGTA
(732)
Asp85Gly,
Gly124Arg,
Ile244Val
Gln7Arg
(CAACGA)
 43.7.3E 
43.7.4B 
9.2 GATGGT
(254),
GGGAGA
(369/371),
ATAGTA
(732)
Asp85Gly,
Gly124Arg,
Ile244Val
 9.2.1A 
9.2.3B 
aNumbering refers to the nucleotide and amino acid positions in the M. mycoides subsp. capri obg gene and protein.
bNone, no TS phenotype; , weak TS phenotype; , strong TS phenotype (as determined by culture assays).
cND, not determined.
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single-amino-acid changes Asp85Asn (GATAAC) and Gly124Arg (GGGAGA or
GGGCGT) grew as well as the control at both temperatures tested and therefore did
not show a TS phenotype (Fig. 2). In contrast, the mutants (7.1, 43.7, and 9.2) with the
single mutation Gly80Glu (GGTGAG) and with the multiple mutations Asp85Gly
(GATGGT), Gly124Arg (GGGAGA), and Ile244Val (TATTGT), with or without a
mutation in nadE (Gln7Arg, CAACGA), showed a marked TS phenotype. Clone 43.7
was the most affected, with a 4-log lag behind the control clone 30.1 still after 144 h of
culture at 40°C (Fig. 2).
As the color change of the medium does not precisely reflect the cell concentration
in a mycoplasma culture, we performed 16S rRNA gene qPCR analyses during the in
vitro culture. While the qPCR curves confirmed the results obtained by the color change
culture assay (Fig. 3), they provided a more precise measure of mycoplasma growth. At
32°C, we observed that the curves were very similar between the M. mycoides subsp.
capri control clone 30.1 and the different mutants tested (Fig. 3A). All bacterial cultures
reached their stationary phase after 72 h of incubation, except for mutant 43.7, which
was slightly delayed and reached its stationary phase after 96 h (24 h later). At 40°C
(Fig. 3B), no growth difference was observed between mutants 11.1, 15.2, and 69.3 and
the control strain 30.1. They all reached the stationary phase at the 48-h time point
(T48), confirming that M. mycoides subsp. capri grows faster at 40°C than at 32°C, but an
1-log decrease in the final bacterial concentration was consistently measured (108
cells · ml1 at 40°C versus 109 cells · ml1 at 32°C) (Fig. 3A and B). Interestingly, the
growth curves of three other mutants did not follow the trend of the control strain. At
40°C, the doubling time of mutants 7.1 and 9.2 appeared to be greatly affected, since
these cells reached the stationary phase at T120 and T144, respectively. In addition,
mutant 43.7 did not appear to grow at all, since the bacterial concentration remained
consistently below 103 cells · ml1 (Fig. 3B), even after 144 h of incubation. However,
according to Fig. 2, a color change from red to yellow could be observed for this mutant
up to a 105 dilution, indicating a residual ability to grow. Consistent with this result,
the qPCR measurements of the in vitro culture done with the 108 dilution did not
FIG 2 Growth monitoring of M. mycoides subsp. capri obg mutants at permissive (32°C) and nonpermissive (40°C) temperatures. M. mycoides subsp. capri obg
mutants were first precultured in SP5 medium at 32°C. At pH 6.4, cell cultures were then serially diluted (101 to 109) and incubated at either 32°C or 40°C
for 8 consecutive days. SP5 medium color change from red to yellow evidenced cell propagation, since glucose utilization during M. mycoides subsp. capri
propagation results in an acid shift. Pictures taken at 48 h and 144 h are shown, as indicated. Control 30.1 corresponds to YCpMmyc1.1 with an intact obg region.
The dotted rectangles indicate tubes (dilution, 108) from which the 100-l aliquots were removed every 24 h from 0 h to 144 h to perform the qPCR analysis
(Fig. 3A and B).
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reveal any growth (Fig. 2, dotted rectangles). Based on these results, mutants 7.1, 9.2,
and 43.7 were selected for further analysis.
Genotypic and phenotypic analyses of the selected M. mycoides subsp. capri
obg subclones. In order to eliminate the possibility of having heterogeneous popula-
tions, the three mutants (7.1, 9.2, and 43.7) were submitted to three rounds of filter
cloning (Fig. 1B). After this procedure, a total of six subclones were selected for each of
the three selected mutants and cultured in SP5 medium supplemented with tetracy-
FIG 3 Temperature sensitivity of the different M. mycoides subsp. capri obg mutants and subclones as measured by qPCR. Bacterial concentrations of the
different M. mycoides subsp. capri obg mutants and subclones were measured at 32°C (A, C, and E) and 40°C (B, D, and F) over time. (A and B) Cultures of the
different M. mycoides subsp. capri obg mutants incubated at 32°C (A) or 40°C (B) were sampled every 24 h for up to 144 h, and bacterial titers were assessed
using a qPCR assay targeting the 16S rRNA gene. (C to F) Similar experiments were performed to estimate the growth of individual subclones derived from
the initial mutant 9.2 (C and D) or mutant 43.7 (E and F) for up to 120 h. Cultures monitored over time for qPCR assays are surrounded by dotted rectangles
(Fig. 2 [for the mutants]; see also Fig. S5 in the supplemental material [for the subclones]). Errors bars represent standard deviations (SD) from three independent
replicates. Statistical differences (t test) between the M. mycoides subsp. capri controls (30.1 or 30.1.1) and the different mutants were determined at each time
point. *, P  0.05; **, P  0.001; ***, P  0.0001.
obg Mutations Result in Attenuation of Mycoplasma
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cline prior to genotypic analysis. For mutants 7.1 and 43.7, all subclones showed an obg
sequence identical to that of the parental clones. However, for mutant 9.2, the
sequencing data of the 6 subclones revealed some sequence heterogeneity. While 4
subclones carried the expected the GATGGT (Asp85Gly), GGGAGA (Gly124Arg), and
TATTGT (Ile244Val) substitutions, 2 others (9.2.2 and 9.2.6) presented a different
mutation in one of the targeted codons, GATAGT (Asp85Ser). This suggested the
coexistence of two populations in the initially selected 9.2 mutant. Consequently,
subclones 9.2.2 and 9.2.6 with an unwanted additional mutation were not analyzed
further.
Phenotypic analysis of the subclones was performed as described above, using two
subclones from each parental mutant (Table 1). After evaluating the temperature
sensitivity phenotype of the subclones by evaluating their growth at two temperatures
(Fig. S5), data from the phenotypic analysis of the subclones that showed the most
pronounced phenotype (43.7.3E, 43.7.4B, 9.2.1A, and 9.2.3B) were confirmed using
qPCR assays (Fig. 3C to F). At 32°C, the cultures of the four subclones reached the
stationary phase at T72, showing a 24-h delay compared to the control strain 30.1.1
(Fig. 3C and E). This delay significantly increased at 40°C, a temperature at which almost
all subclones reached their optimum growth beyond 96 h of incubation, in contrast to
24 h for the control strain 30.1.1. Only subclone 43.7.3E reached its stationary phase
after 72 h of incubation (Fig. 3F). As observed for growth curves, the subclones derived
from mutant 9.2 (9.2.1A and 9.2.3B) behaved differently from the parental mutant, as
they both grew slow, especially at 40°C (Fig. 3D). In fact, their phenotype became
almost identical to that of subclones 43.7.3E and 43.7.4B, which contain the same
mutations in the obg gene (Asp85Gly [GATGGT], Gly124Arg [GGGAGA], and
Ile244Val [TATTGT]) plus a mutation in nadE (Gln7Arg [CAACGA]). This discrepancy,
most likely caused by the presence of a mixed population in mutant 9.2, suggested that
the mutation GATAGT (Asp85Ser) detected in some 9.2 subclones probably does not
confer a TS phenotype.
The culture assays (Fig. S5) together with the qPCR measurements confirmed that
subclones 43.7.3E, 43.7.4B, 9.2.1A, and 9.2.3B exhibit a marked TS phenotype.
Whole-genome sequencing of subclones derived from the 30.1 control and from the
7.1, 9.2, and 43.7 mutants indicated a number of mutations other than those in the obg
gene, but none of these correlated with the TS phenotype observed (Table S2).
Evaluation of the virulence of the 9.2.3B obg subclone in an experimental
animal model. Among the four M. mycoides subsp. capri obg subclones (43.7.3E,
43.7.4B, 9.2.1A, and 9.2.3B) that were characterized as described above, subclone 9.2.3B,
which carried 3 mutations in the obg gene and showed the strongest TS phenotype,
was selected for subsequent in vivo testing of attenuation using a caprine infection
model.
Two groups of eight male goats, housed in separated rooms, were infected tran-
stracheally with either M. mycoides subsp. capri YCpMmyc1.1 (22, 23) (control group) or
M. mycoides subsp. capri obg subclone 9.2.3B (obg group). After two injections, one at
0 days postinfection (dpi), with 108 CFU, and the other at 7 dpi, with 109 CFU, animal
health status was monitored daily by measuring key parameters, such as body weight,
heartbeat, breathing frequency, and body temperature (Fig. 4). The following endpoint
criteria for animal euthanasia were applied: a body temperature higher than 40.5°C for
more than 3 consecutive days, the appearance of clinical signs indicating moderate to
severe pain or distress, weight loss of more than 10% within 7 days, and a breathing
frequency higher than 50 breaths · min1 for more than 3 days. In the control group,
5 goats out of 8 met the endpoint criteria before the envisaged end of the trial (i.e.,
35 dpi) and were euthanized in the course of the experiment, whereas only 1 goat
(animal CM135) out of 8 met the same criteria in the obg group (Fig. 4A) (24). M.
mycoides subsp. capri was cultured from 3 out of 8 animals that were infected with the
control strain YCpMmyc1.1. The time points of M. mycoides subsp. capri isolation
coincided with severe pyrexia. Bacterial titers ranged between 100 and 1,000 CFU ·
ml1 (24). Animals that did not develop the disease had body temperatures ranging
Lartigue et al.
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between 38°C and 39.5°C, which represents the physiological range for goats (Fig. 4B).
Within the group infected with M. mycoides subsp. capri YCpMmyc1.1, those animals
showing signs of disease developed fever (rectal temperature of 39.5°C) between
days 3 and 10 after the first injection (Fig. 4B), and animal CM135 from the obg group
FIG 4 Survival rates and clinical parameters measured during in vivo testing of M. mycoides subsp. capri obg 9.2.3B (obg group) and M. mycoides subsp. capri
YcpMmyc1.1 (control group). (A) The difference in survival rates (Kaplan-Meier curve) is significant according to both the Mantel-Cox test (P 0.0351) and the
Gehan-Breslow-Wilcoxon test (P 0.0325). There were 8 goats per group. (B) Rectal temperature measured daily, shown as an average per group. The difference
in average temperatures between the groups was significant on days 9 and 10 postinfection (day 9, P 0.0006; day 10, P 0.0053) using the Mann-Whitney
test, coinciding with the peak of severity of disease in the group that received the M. mycoides subsp. capri YcpMmyc1.1 strain. (C) The white blood cell (WBC)
count (measured twice weekly) was relatively stable throughout the trial, and no major difference between the groups was observed at any time point. (D) Both
groups gained weight, measured three times weekly, continuously during the trial. (E) Respiratory rate, measured daily, remained within the normal range
throughout the study. (F) Heart rate was measured daily and remained within the normal range for both groups. Arrows indicate days of infection (day 0, 108
CFU per animal; day 7, 109 CFU per animal). All graphs show the average measured parameters per group, with error bars showing SD.
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showed fever starting at 13 dpi (data not shown). In most of the animals showing fever,
body temperature reached 41°C in less than 3 days. In the obg group, the heart rate and
breathing rate remained within the normal ranges for all animals, including animal
CM135, throughout the study (Fig. 4E and F). We cultivated M. mycoides subsp. capri
from the blood of the animals of the obg group, and only blood from the animal
(CM135) that succumbed to disease gave a positive culture indicating bacteremia, with
a titer of 103 CCU · ml1. Cultivation of M. mycoides subsp. capri from synovial fluid,
urine, and pleural fluid of the same animal did not yield any positive cultures.
Necropsy of animals from the control group revealed severe and extensive necrosis,
edema, and inflammation of the skin, subcutis, skeletal muscle of the neck, and the
trachea around the site of inoculation in five animals. Histologically, there was extensive
coagulation necrosis of these tissues surrounding the trachea in the vicinity of the
inoculation site and a marked infiltration of neutrophilic granulocytes (Fig. S6a). These
areas were surrounded by a rim of infiltration with mainly macrophages and lympho-
cytes. Regional lymph nodes showed purulent to necrotizing lymphadenitis, and there
were multifocal neutrophilic infiltrates in the spleen. In one animal, there were multi-
focal, randomly distributed small areas of necrosis in neutrophilic infiltrates in the liver.
These lesions were suggestive of septicemic spread of M. mycoides subsp. capri from
the site of inoculation. Three animals of this group (animals CM045, CM047, and CM191)
did not show macroscopic or histological lesions. Animal CM135 in the obg group had
lesions similar to those in the control group (Fig. S6b). Overall, the data clearly
demonstrated that even though one animal in the obg group developed disease and
had to be euthanized, the virulence ofM. mycoides subsp. capri obg subclone 9.2.3B was
attenuated compared to its parental strain.
Genotypic analysis of the revertant iCM135. In order to find out the reason for
the loss of one animal in the obg group (Fig. 4A), the mycoplasma strain isolated from
blood samples of the euthanized animal (iCM135 strain) was subjected to further
analyses. Whole-genome sequencing showed that iCM135 carried a single reversion in
one of the target mutations within the obg gene. Indeed, compared to the original TS
M. mycoides subsp. capri obg subclone 9.2.3B, the GATGGT (Asp85Gly) triplets re-
verted back to GAT (Gly85Asp) in the iCM135 strain. The temperature sensitivity of
iCM135 was analyzed in vitro using culture assays at 32°C or 40°C along with the M.
mycoides subsp. capri control subclone 30.1.1 (intact obg). The experiment clearly
showed that the iCM135 strain lost its temperature sensitivity and recovered a non-
temperature-sensitive (TS) phenotype that is similar to that of the parental strain
(Fig. S7) and that the loss of the TS phenotype is probably due to the reversion
observed at position 85 (Table S2). It should be stressed that a similar reversion of
phenotype associated with reversion at position 85 was also observed in vitro during
culture of subclone 9.2.1C at 40°C (Fig. S7).
Experimental challenge following infection with the 9.2.3B obg subclone. Since
seven of eight goats infected with the 9.2.3B obg subclone survived after 35 dpi, we
evaluated whether infection in these animals had triggered an immune response that
would provide a certain degree of protection against an experimental challenge. The
animals were challenged transtracheally with the M. mycoides subsp. capri GM12 strain
(25). It should be noted that this strain is different from the M. mycoides subsp. capri
YCpMmyc1.1 strain used as the control in the above-described experiment because it
has not been submitted to a round of yeast cloning-genome transplantation followed
by triple filter cloning. Therefore, the M. mycoides subsp. capri GM12 strain, at a low
passage number, is known for its high pathogenicity, causing septicemia and death
when administered at a high dose (27). At 0 days postchallenge (dpc), the seven
animals were infected transtracheally with 109 CFU of the M. mycoides subsp. capri
GM12 strain, and animal health status was monitored daily for 28 days by measuring
parameters such as body weight, heartbeat, breathing frequency, and body tempera-
ture (Fig. 5). Between 4 dpc and 10 dpc, 6 out of the 7 goats met the endpoint criteria
and were euthanized, with only 1 animal (CM118) surviving until the end of the
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experiment (Fig. 5A). As expected with this highly pathogenic and septicemic strain of
M. mycoides subsp. capri, infection resulted in a peak body temperature reaching41°C
for 5 out of the 6 animals that were euthanized. The M. mycoides subsp. capri challenge
strain GM12 was isolated from the blood of 6 of the 7 animals. The bacterial titers
ranged from 104 to 1010 CFU · ml1. The only animal for which the cultures remained
negative was animal CM118, which survived until the end of the experiment, at 30 days
postchallenge. Other clinical parameters were also affected although not uniformly
among these animals (Fig. 5C to F).
Pathological lesions in 6 out of 7 of the M. mycoides subsp. capri GM12-inoculated
animals were similar to those of the above-described control group, with massive
FIG 5 Experimental challenge of surviving goats following infection with the 9.2.3B obg subclone. Shown are survival rates and clinical
parameters measured during in vivo challenge with wild-type M. mycoides subsp. capri GM12 (109 CFU per animal) of the 7 animals that
survived the initial infection with M. mycoides subsp. capri obg 9.2.3B. Due to the small number of animals and the heterogeneity of data,
individual curves for clinical parameters are shown in panels B to F. (A) Six out of the seven animals were euthanized due to severity of
disease between days 4 and 10 postchallenge. (B) All but one of the seven animals had fever (defined as a rectal temperature of39.5°C),
with peak temperatures ranging from 40.3°C to 41.8°C. One animal did not show an elevated temperature (animal CM118). (C) The white
blood cell count dropped initially in 5 of the 7 animals but remained within the normal range throughout the study. (D) Weight loss was
seen during severe disease in 5 animals. Goat CM118 lost weight after the other animals in the group had been euthanized but started
to recover at around 20 days postchallenge. (E) Breathing frequency was within the normal range throughout the challenge experiment.
(F) At the peak of severity of disease, the individual heart rates of animals CM193, CM051, CM129, and CM126 increased. The average heart
rate remained within the normal range throughout the trial.
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necrosis and mainly neutrophilic inflammation in the soft tissues and the trachea of the
neck extending from the inoculation site (Fig. S6c). All animals showed histopatholog-
ical signs of septicemia, characterized as multifocal acute necrosis and neutrophilic
infiltration in the spleen. In addition, three animals developed mild, purulent broncho-
pneumonia. Animal CM118 did not show any macroscopic or histological lesions.
DISCUSSION
Using synthetic biology approaches, the essential gene obg encoding a P-loop
GTPase was mutated on the M. mycoides subsp. capri genome, cloned in yeast, and
subsequently transplanted into Mycoplasma capricolum recipient cells to obtain a set of
M. mycoides subsp. capri mutants carrying various mutations. The targeted modifica-
tions of obg reproduced mutations that are known to be associated with a
temperature-sensitive phenotype in various bacteria, including in a commercial live
vaccine of M. synoviae.
Among the single obg mutations that were previously associated with a TS
phenotype in E. coli, B. subtilis, and M. synoviae, the only one that showed a significant
TS phenotype in M. mycoides subsp. capri is Gly80Glu (mutant 7.1) (Fig. 2). This
mutation has been described in detail in Caulobacter crescentus and was also charac-
terized by a marked TS phenotype associated with alterations in the cell cycle (21). In
contrast, the single mutation described in the TS vaccine strain of M. synoviae
(Gly124Arg) did not, by itself, produce a TS phenotype in M. mycoides subsp. capri.
Recently, complementation of the Gly124Arg substitution in M. synoviae with a wild-
type copy of the obg gene did not result in a TS phenotype (10), but some of the
growth parameters, including growth rate and cell viability, were at least partially
restored; it should be stressed that in this case, complemented clones expressed both
wild-type Obg and the protein with the Gly124Arg substitution. In the obg mutants
with more than one mutation, the complex interplay among them is probably due to
structure constraints. For example, the reversion at position 85 (Gly85Asp) was associ-
ated with the loss of the TS phenotype in the 9.2.3B mutant, although the single
mutation Asp85Asn (mutant 11.1) did not produce a significant TS phenotype in M.
mycoides subsp. capri. As the replacement at this position has been done using two
different amino acids (Gly and Asn), we cannot exclude the possibility that one change
is more drastic than the other one regarding the growth of M. mycoides subsp. capri at
a nonpermissive temperature.
The set of mutants that was obtained in this study finally resulted in a range of TS
phenotypes. The mutant that was the most severely affected in its growth at 40°C was
selected because the multiple mutations (at least the Asp85Gly and the Gly124Arg
mutations) were considered to confer a higher level of safety against possible genetic
reversion. These two mutations did not prove to be sufficient, since a single reversion
at position 85 (Gly85Asp) was associated with the loss of the TS phenotype both in
vivo (mutant iCM135) and in vitro (subclone A9.2.1C40). This indicates that a structural
change in the protein that leads to the TS phenotype occurs only when both of the
two mutations (Gly85Asp and Gly124Arg) are present, possibly together with the third
mutation (Ile224Val). Therefore, the reversion in one of them was enough to lose the
TS phenotype in M. mycoides subsp. capri. Obviously, the reversion of these mutations
is a problem if one envisages obtaining safe vaccine strains with this approach. In fact,
this reversion to the TS phenotype is already known for the vaccine strain of M.
synoviae that was produced by chemical mutagenesis, but this attenuation is most
likely due to other mutations in other genes, such as the ones encoding the oligopep-
tide permease (Opp) system (6, 10, 26).
A novel caprine challenge model has been established for M. mycoides subsp. capri
GM12 (24, 27), which we basically followed, with slight modifications, as reported
recently (24). This challenge model proved to be robust and reproducible (24, 27).
Another caprine challenge model using an atypical M. mycoides subsp. capri strain was
reported elsewhere (28), but as the number of infected animals was small and the
outcome differed between groups markedly, we opted not to follow this challenge
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model. The model of infection performed here is a significant advancement, as there is
a general lack of animal models for studying mycoplasma pathogenicity, which is
mostly due to the high host specificity of mycoplasmas. However, this animal model
has its own advantages as well as limits. Its main advantage is that it allows evaluation
of the attenuation of mutants when derived from a strongly pathogenic strain such as
M. mycoides subsp. capri GM12. Within a few days, the survival curves (Fig. 4) together
with the data on bacteremia provide the main tools for evaluation of the outcome of
infection. The weight of each clinical parameter, including body temperatures, is more
difficult to evaluate because we used outbred goats that are genetically heteroge-
neous. In addition, as shown in this study, the high dose of infection with mutants
provides the possibility of detecting pathogenic revertants. However, the limits of this
animal model also need to be recognized. The transtracheal application of the 9.2.3B
obg subclone was selected for comparison of virulence with the parental strain YCpM-
myc1.1. This route was not meant to be used as prospective immunization route.
However, we opted to challenge the 7 goats that survived the first phase of the
experiment (35 dpi) because we expected the induction of an immune response, and
it provides a comparison with similar results obtained with a GM12 glfmutant defective
in capsule biosynthesis (24). Whereas 3 of the 8 animals infected with the glf mutant
survived, only 1 of the 7 animals infected in this study with the obg mutant survived.
This difference is not significant. It is difficult to discuss much more about this
difference without a full analysis of the immune response in individual animals; our
preliminary attempts using enzyme-linked immunosorbent assays (ELISAs) and immu-
noblotting did not provide meaningful results because of the high background of
antibodies cross-reacting with M. mycoides subsp. capri antigens in the goats. This is
likely due to the exposure of these animals to a number of parasites before being
selected for this trial. Finally, it should also be stressed that very little is known about
the immune determinants that would provide protection from challenge with highly
virulent M. mycoides subsp. capri.
Until now, the tools from synthetic biology applied to Mycoplasma species have
been mostly limited to building a minimal cell (20). However, we have shown that these
tools are also useful for the elucidation of gene functions (29) and for the deciphering
of host-pathogen interactions (30). The versatility of these approaches that combine
in-yeast genome engineering and back-transplantation into a recipient cell is further
demonstrated in the present study by showing our ability to generate targeted point
mutations within the essential obg gene. Such an achievement was previously impos-
sible using the genetic tools available for any Mycoplasma species. Since it is now
possible to use synthetic biology tools for most of the ruminant-pathogenic Myco-
plasma species that are closely related to M. mycoides subsp. capri (31), new strategies
of vaccine design based on precise and multiple targets using genome engineering
have become fully realistic. Within this global aim, the TS phenotype resulting from
obg mutations described here is of interest if combined with (i) other mutations that
hamper completely the possibility of reversion to a virulent phenotype and (ii) other
deletion(s), such as deletion of the nonessential glpO gene known to be involved in the
production of H2O2 (32). Owing to this new animal model, we now have the possibility
of evaluating the attenuation of virulence of different mutants resulting from genome
engineering approaches and the immune response providing protection against an
experimental challenge.
MATERIALS AND METHODS
Bacterial and yeast strains and culture conditions. Competent E. coli cells (ElectroMAX DH10B;
Invitrogen) [F mcrA(mrr-hsdRMS-mcrBC) 80dlacZM15 lacX74 recA1 endA1 araD139 Δ(ara leu)7697
galU galK  rpsL nupG] served as the host for cloning experiments and plasmid propagation. E. coli cells
transformed with plasmids were grown at 37°C in Luria-Bertani (LB) broth or agar medium supplemented
with 100 g · ml1 of ampicillin.
Wild-type Mycoplasma mycoides subsp. capri strain GM12 (25) and other M. mycoides subsp. capri
derivatives were cultured in SP5 medium as described previously (31). Tetracycline was added to the
medium when needed at 5 g · ml1. For genome transplantation experiments, restriction-free Myco-
plasma capricolum subsp. capricolum (McapΔRE) recipient cells (22) were grown at 30°C in superoptimal
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broth (SOB) supplemented with 17% (vol/vol) fetal bovine serum, 1% (wt/vol) glucose, 0.002% (wt/vol)
phenol red, and penicillin at 0.5 g · ml1 (SOB medium) (33).
Saccharomyces cerevisiae strain VL6-48N (MAT trp1-Δ1 ura3-Δ1 ade2-101 his3-Δ200 lys2 met14 cir°)
(34) was cultured at 30°C in YPDA (yeast extract peptone dextrose adenine) medium (Clontech)
according to a standard protocol (35). Yeast transformed with mycoplasma genomes was grown in
minimal SD (synthetic defined) base medium (Clontech) complemented with histidine dropout supple-
ment (Clontech) (SD-His medium).
M. mycoides subsp. capri genome engineering in yeast. The genome of the modified M. mycoides
subsp. capri clone YCpMmyc1.1 (strain GM12) was previously cloned into S. cerevisiae strain VL6-48N (22).
Targeted nucleotides corresponding to the amino acids at position 80, 85, or 124 of the M. mycoides
subsp. capri Obg protein (Fig. 1A; see also Fig. S1 in the supplemental material) were mutated in the
YCpMmyc1.1 genome cloned into yeast by using the TREC-IN (tandem repeat endonuclease cleavage-
insertion) method as previously described (36). The experimental procedure used to obtain these
engineered genomes is shown in Fig. 1B and detailed in the legend of Fig. S2 in the supplemental
material (primers used during the procedure are listed in Table S1). At the end of the process,
YCpMmyc1.1-obg genomes were obtained and contained mutations at either position 239/240, 253/255,
or 369/371 of the obg gene, which corresponds to position 80, 85, or 124 of the Obg protein, respectively.
To check this, total DNA was extracted from all selected yeast recombinants, and the DNA was analyzed
by simplex PCR (Table S1), multiplex PCR, and pulsed-field gel electrophoresis (PFGE) as described
previously (29) (Fig. S3). The presence of the mutations was confirmed by sequencing the 1,601-bp obg
PCR fragment obtained using the primers obgF1 and obgR2 (Fig. S2). For multiplex PCR, a set of 11
different pairs of primers was used as previously described (22) (Table S1).
The TREC-IN method was also used to build a genome equivalent to the mutant 43.7 genome but
with a repaired nadE sequence. Using the primer pair obgF1/obgR3 (Table S1) and mutant 43.7 genomic
DNA, we amplified the obg gene with changes at positions 254, 369, 371, and 732 plus a 113-bp segment
located upstream of the obg gene. This amplicon was then used as a template for PCR with primers
cassette B-forward-F1 and cassette D-reverse-R1 to create a minicassette, named minicassette BC, with
60-bp overlaps with minicassette A at its 5= end and 60-bp overlaps with the sequence downstream of
5= Kan (positions 1 to 515) of the YCpMmyc1.1-obg::URA3 genome, at its 3= end. Minicassettes BC and
A were finally cotransformed into VL6-48N yeast clone 34 harboring the YCpMmyc1.1-obg::URA3
genome (step 2 of the TREC-IN method). The next steps of the TREC-IN method as well as all genotypic
tests were performed as described above.
Back-transplantation of the engineered YCPMmyc1.1-obgmod genomes into mycoplasma re-
cipient cells to produce the M. mycoides subsp. capri obg mutants. In-yeast-engineered M. mycoides
subsp. capri genomes were isolated in agarose plugs and transplanted back into restriction-free M.
capricolum subsp. capricolum (McapΔRE) recipient cells as previously described (22, 37). The resulting
transplants were selected on SP5 medium plates supplemented with 5 g · ml1 of tetracycline. After 3
successive passages in liquid medium, transplants were analyzed by PCR using M. mycoides subsp.
capri-specific primers (Table S1), multiplex PCR (Table S1), and PFGE, as previously described (22). The obg
gene was systematically amplified using the primer pair Obg-F1/ObgR1 (Fig. S2B) and sequenced in order
to verify the presence of the desired mutations.
Mutants showing temperature-sensitive phenotypes were submitted to three successive rounds of
filter cloning using 0.22-m sterilizing-grade filters (38). Subclones were once more assessed for their
temperature-sensitive properties, and their whole genomes were sequenced using Illumina next-
generation sequencers (see the supplemental material). Mutant and subclone names and main charac-
teristics are summarized in Table 1.
Assessment of temperature sensitivity by serial dilution and qPCR. Mutants and subclones were
grown at 32°C in SP5 medium until the pH reached 6.4. The temperature sensitivity of the samples was
then analyzed by serial dilutions (101 to 109) of the cell cultures in SP5 medium, followed by an
incubation period of 8 days at a permissive temperature (32°C) or a nonpermissive temperature (40°C).
Culture color change was monitored daily and compared to that of a culture of WT M. mycoides subsp.
capri strain GM12 grown under the same conditions. The cell concentration of each initial culture (pH 6.4)
was determined by plating dilutions on SP5 plates. Just before putting the samples into the incubator
(T0) and then every 24 h during 6 days (T24 to T144), a 100-l aliquot was taken from the “108 dilution
tube” (for the mutants) and from the “105 dilution tube” (for the subclones) for qPCR assays. These qPCR
assays were performed using a protocol described previously (31). Briefly, qPCR measurements were
conducted in 96-well plates using the SsoFast EvaGreen supermix (Bio-Rad) on the LightCycler 480
real-time PCR system (Roche) according to the manufacturers’ instructions. Standard curves used to
quantify the numbers of M. mycoides subsp. capri genomes were run independently for each assay by
using purified genomic DNA (Wizard genomic DNA purification kit; Promega), with samples containing
between 102 and 108 genomes. Measurements were done in triplicates for all samples. Data analyses
were performed using GraphPad Prism statistical software version 7. All qPCR data were previously log
transformed to meet model assumptions, and the Benjamini-Hochberg method (39) was used to adjust
the false discovery rate (FDR) associated with the test. Analyses were done using an unpaired (indepen-
dent) t test to compare the concentrations (means) of the different mutants with those of the M.
mycoides subsp. capri controls (30.1 or 30.1.1) at each time point.
Animal studies. The animal experiments were performed under strict ethical rules (see “Ethics
statement,” below). Briefly, 16 male crossbred goats (Capra hircus), 1 to 2 years of age, were randomly
selected from the International Livestock Research Institute (ILRI) ranch in Kapiti (see the supplemental
material for details). Five days before experimental infection, all animals were transferred to the animal
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biosafety level 2 (ABSL2) unit and split randomly into two groups of eight animals (positive-control and
obg groups), and each group was housed in a separate room. On day 0 postinfection (p.i.) and day 7 p.i.,
goats of the positive-control group and the obg group were infected transtracheally (the injection site
was 5 to 10 cm distal from the larynx) with M. mycoides subsp. capri YCpMmyc1.1 and M. mycoides subsp.
capri YCpMmyc1.1-obg, respectively. On day 0 p.i., each animal was infected with a 1-ml liquid culture
containing 108 CFU, followed by a flush with 5 ml of phosphate-buffered saline (PBS); on day 7 p.i., this
procedure was repeated, except that each animal was infected with a liquid culture containing 109 CFU.
The animals were allowed to move freely within the ABSL2 unit and received hay and water ad libitum
as well as pellets in the morning. Heart rate, breathing frequency, rectal temperature, and oxygen blood
saturation were measured daily in the morning hours. Animals showing either a body temperature of
40.5°C for3 consecutive days, moderate to severe pain or distress, weight loss of10% within 7 days,
or a breathing frequency of 50 breaths/min for 3 days were euthanized. More information regarding
the group infected with YCpMmyc1.1 were described previously by Jores et al. (24).
Ethics statement. All protocols of this study were designed and performed in strict accordance with
Kenyan legislation for animal experimentation and were approved by the institutional animal care and
use committee (IACUC) (reference no. IACUC-RC2016-04, signed by Roger Pelle). Since 1993, the ILRI has
complied voluntarily with the United Kingdom’s Animals (Scientific Procedures) Act 1986 (http://www
.homeoffice.gov.uk/science-research/animal-research/), which contains guidelines and codes of practice
for the housing and care of animals used in scientific procedures. The study reported here was carried
out in strict accordance with the recommendations in the standard operating procedures of the ILRI
IACUC (ILRI IACUC ref no. 2016.06) and with adequate consideration of the 3 R’s (replacement of animal
with nonanimal techniques, reduction in the number of animals used, and refinement of techniques and
procedures that reduce pain and distress). As this project also received financial support from the NSF
(NSF proposal IOS-1110151 entitled BREAD: Toward Development of a Vaccine for Contagious Bovine
Pleuropneumonia [CBPP]) awarded to the J. Craig Venter Institute (JCVI), the protocols of this study were
also approved by the JCVI’s own IACUC. The project was approved initially by the IACUC on 17 August
2011, reapproved on 6 October 2014 (no. 011-14), and signed by Mark Adams, JCVI Scientific Director.
Pathomorphological and histological analyses. Complete necropsy was performed on all animals.
Tissue samples of the neck region around the inoculation site and all internal organs were fixed in 10%
buffered formalin for 72 h and subsequently routinely processed for paraffin embedding. Tissue sections
were cut at 3 m, stained routinely with hematoxylin and eosin (H&E), and evaluated by a board-certified
pathologist.
Data availability. We declare that the data supporting the findings of this study are available within
the paper and its supplemental material. The sequences from this study are available from the NCBI
under SRA accession no. PRJNA510711.
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